Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL14688080 | 0.97 | KDM4E (0.43) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL8998717 | 0.87 | AOC3 (0.49) | KDM4EALDH1A1HPGDHSD17B10TP53 | |
| SCHEMBL19380526 | 0.87 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL668928 | 0.86 | ATM (0.40) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL19380525 | 0.86 | TSHR (0.42) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL668910 | 0.83 | MTNR1A (0.40) | ALDH1A1HPGDATMSMN1; SMN2NPSR1 | |
| SCHEMBL19380554 | 0.83 | BAZ2B (0.46) | ALDH1A1HPGDATMSMN1; SMN2NPSR1 | |
| SCHEMBL3973908 | 0.80 | XDH (0.39) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL27568977 | 0.80 | GABRP (0.39) | KDM4EALDH1A1HTTSMN1; SMN2NPC1 | |
| SCHEMBL8998825 | 0.79 | PARP1 (0.44) | KDM4EALDH1A1HPGDHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | claimed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | claimed |
| EP-1601354-B1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2013-11-13 | — | — | EP | claimed |
| EP-1601354-A4 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2009-08-12 | — | — | EP | claimed |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION | 2009-06-11 | — | — | US | claimed |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | HORMANN ROBERT EUGENE | 2008-10-16 | — | — | US | claimed |
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2007-12-13 | — | — | US | claimed |
| US-7304162-B2 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | claimed |
| EP-1601354-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2005017126-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | RHEOGENE, INC. (DE CORPORATION) | 2004-09-02 | — | — | US | claimed |
| EP-0729953-A2 | A process for producing a 2-substituted-3,4-fused heterocyclic benzoic acid | ROHM AND HAAS COMPANY (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0602794-A2 | Insecticidal N'-substituted-N, N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1994-06-22 | — | — | EP | claimed |
| EP-4274898-A2 | CHIMERIC RECEPTOR THERAPY | Precigen, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4251278-A1 | HUMAN PAPILLOMA VIRUS VACCINES AND USES OF THE SAME FOR HPV ASSOCIATED DISEASES | Precigen, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022150732-A2 | CHIMERIC RECEPTOR THERAPY | PRECIGEN, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-0729934-A2 | A process for producing a 3-alkoxy-2-(substituted)benzoic acid or an ester thereof | ROHM AND HAAS COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0729953-A2 | A process for producing a 2-substituted-3,4-fused heterocyclic benzoic acid | ROHM AND HAAS COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5530028-A | CONTROLS INSECTS OF THE ORDER LEPIDOPTERA | ROHM AND HAAS COMPANY (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0602794-A2 | Insecticidal N'-substituted-N, N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1994-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | NR0B1, NR0B2, NR5A2 | KDM4E 1288/4885ALDH1A1 3889/4885HPGD 1199/4885 |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | NR0B1, NR0B2, NR5A2 | KDM4E 1288/4885ALDH1A1 3889/4885HPGD 1199/4885 |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | NR2E3, ESRRB, NR0B2 | KDM4E 931/4885ALDH1A1 4171/4885HPGD 1634/4885 |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | ESRRB, NR2E3, NR5A1 | KDM4E 3256/4885ALDH1A1 4104/4885HPGD 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.